Computer and mobile technology interventions to promote medication adherence and disease management in people with thalassemia
Referencias
Additional references
Abetz L, Baladi JF, Jones P, Rofail D. The impact of iron overload and its treatment on quality of life: results from a literature review. Health and Quality of Life Outcomes 2006;4:73.
Angelucci E. Hematopoietic stem cell transplantation in thalassemia. Hematology: The Education Program of the American Society of Hematology 2010;1:456‐62.
Badawy SM, Thompson AA. Management challenges in thalassemia. In: Abutalib SA, Connors JM, Ragni MV editor(s). Nonmalignant Hematology, Expert Clinical Review: Questions and Answer. Springer International Publishing, Switzerland, 2016.
Badawy SM, Thompson AA, Liem RI. Technology access and smartphone app preferences for medication adherence in adolescents and young adults with sickle cell disease. Pediatric Blood & Cancer 2016;63(5):848‐52.
Badawy SM, Kuhns LM. Economic evaluation of text‐messaging and smartphone‐based Interventions to improve medication adherence in adolescents with chronic health conditions: a systematic review. JMIR Mhealth and Uhealth 2016;4(4):e121.
Badawy SM, Kuhns LM. Texting and mobile phone app interventions for improving adherence to preventive behavior in adolescents: a systematic review. JMIR Mhealth and Uhealth 2017;5(4):e50.
Badawy SM, Sinno MG, Kaviany S, O’Dwyer L, Kuhns LM. Text messaging and smartphone app interventions to improve medication adherence in adolescents with chronic conditions: a systematic review. JMIR Mhealth and Uhealth 2017;5(5):e66.
Bandura, A. Self‐efficacy: toward a unifying theory of behavioral change. Psychological Review 1977;84:191‐215.
Bonoto BC, de Araujo VE, Godoi IP, de Lemos LL, Godman B, Bennie M, et al. Efficacy of mobile apps to support the care of patients with diabetes mellitus: a systematic review and meta‐analysis of randomized controlled trials. JMIR Mhealth and Uhealth 2017;5(3):e4.
Cappellini MD, Bejaoui M, Agaoglu L, Porter J, Coates T, Jeng M, et al. Prospective evaluation of patient‐reported outcomes during treatment with deferasirox or deferoxamine for iron overload in patients with beta‐thalassemia. Clinical Therapeutics 2007;29(5):909‐17.
Christakis NA. Social networks and collateral health effects. BMJ 2004;329(7459):184‐5.
Cobb S. Presidential Address‐1976. Social support as a moderator of life stress. Psychosomatic Medicine 1976;38:300‐14.
Cohen S, Wills, TA. Stress, social support, and the buffering hypothesis. Psychological Bulletin 1985;98(2):310‐57.
Crosby LE, Ware RE, Goldstein A, Walton A, Joffe NE, Vogel, C, et al. Development and evaluation of iManage: a self‐management app co‐designed by adolescents with sickle cell disease. Pediatric Blood & Cancer 2017;64(1):139‐45.
de Jongh T, Gurol‐Urganci I, Vodopivec‐Jamsek V, Car J, Atun R. Mobile phone messaging for facilitating self‐management of long‐term illnesses. Cochrane Database of Systematic Reviews 2012, Issue 12. [DOI: 10.1002/14651858.CD007459.pub2]
Deeks JJ, Higgins JPT, Altman DG on behalf of the Cochrane Statistical Methods Group. Chapter 9: Analysing data and undertaking meta‐analysis. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
DiMatteo MR, Giordani PJ, Lepper HS, Croghan TW. Patient adherence and medical treatment outcomes: a meta‐analysis. Medical Care 2002;40(9):794‐811.
Cochrane Effective Practice, Organisation of Care (EPOC). EPOC Resources for review authors, 2017. What study designs should be included in an EPOC review and what should they be called?. Available at: epoc.cochrane.org/epoc‐resources‐review‐authors (accessed 15 June 2017).
Evangeli M, Mughal K, Porter JB. Which psychosocial factors are related to chelation adherence in thalassemia? A systematic review. Hemoglobin 2010;34(3):305‐21.
Gurol‐Urganci I, de Jongh T, Vodopivec‐Jamsek V, Atun R, Car J. Mobile phone messaging reminders for attendance at healthcare appointments. Cochrane Database of Systematic Reviews 2013, Issue 12. [DOI: 10.1002/14651858.CD007458.pub3]
Haghpanah S, Zarei T, Zahedi Z, Karimi M. Compliance and satisfaction with deferasirox (Exjade(R)) compared with deferoxamine in patients with transfusion‐dependent beta‐thalassemia. Hematology 2014;19(4):187‐91.
Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration 2011. Available from handbook.cochrane.org.
Higgins JPT, Deeks JJ, editor(s). Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Higgins JPT, Altman DG, Sterne JAC, editor(s) on behalf of the Cochrane Statistical Methods Group and the Cochrane Bias Methods Group. Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Higgins JPT, Deeks JJ, Altman DG, editor(s) on behalf of the Cochrane Statistical Methods Group. Chapter 16: Special topics in statistics. In: Higgins JPT, Green S, editor(s). Cochrane Handbook of Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Higgs DR, Gibbons RJ. The molecular basis of alpha‐thalassemia: a model for understanding human molecular genetics. Hematology/Oncology Clinics of North America 2010;24(6):1033‐54.
Jonassaint CR, Shah N, Jonassaint J, De Castro L. Usability and feasibility of an mHealth intervention for monitoring and managing pain symptoms in sickle cell disease: the sickle cell disease mobile application to record symptoms via technology (SMART). Hemoglobin 2015;39(3):162‐8.
Lee WS, Toh TH, Chai PF, Soo TL. Self‐reported level of and factors influencing the compliance to desferrioxamine therapy in multitransfused thalassaemias. Journal of Paediatrics and Child Health 2011;47(8):535‐40.
Lenhart, A. Teens, Social Media & Technology Overview 2015. www.pewinternet.org/2015/04/09/teens‐social‐media‐technology‐2015/ (accessed prior to 15 June 2017).
Leonard S, Anderson LM, Jonassaint J, Jonassaint C, Shah N. Utilizing a novel mobile health "Selfie" application to improve compliance to iron chelation in pediatric patients receiving chronic transfusions. Journal of Pediatric Hematology/Oncology 2017;39(3):223‐9.
Lin H, Wu X. Intervention strategies for improving patient adherence to follow‐up in the era of mobile information technology: a systematic review and meta‐analysis. PloS One 2014;9:e104266.
Liu Q, Abba K, Alejandria MM, Sinclair D, Balanag VM, Lansang MA. Reminder systems to improve patient adherence to tuberculosis clinic appointments for diagnosis and treatment. Cochrane Database of Systematic Reviews 2014, Issue 11. [DOI: 10.1002/14651858.CD006594.pub3]
Loiselle K, Lee JL, Szulczewski L, Drake S, Crosby LE, Pai AL. Systematic and meta‐analytic review: medication adherence among pediatric patients with sickle cell disease. Journal of Pediatric Psychology 2016;41(4):406‐18.
Martin A, Thompson AA. Thalassemias. Pediatric Clinics of North America 2013;60(6):1383‐91.
Michie S, Richardson M, Johnston M, Abraham C, Francis J, Hardeman W, et al. The behavior change technique taxonomy (v1) of 93 hierarchically clustered techniques: building an international consensus for the reporting of behavior change interventions. Annals of Behavioral Medicine 2013;46(1):81‐95.
Modi AC, Pai AL, Hommel KA, Hood KK, Cortina S, Hilliard ME, et al. Pediatric self‐management: a framework for research, practice, and policy. Pediatrics 2012;129(2):e473‐85.
Payne KA, Rofail D, Baladi JF, Viala M, Abetz L, Desrosiers MP, et al. Iron chelation therapy: clinical effectiveness, economic burden and quality of life in patients with iron overload. Advances in Therapy 2008;25(8):725‐42.
Pfaeffli Dale L, Dobson R, Whittaker R, Maddison R. The effectiveness of mobile‐health behaviour change interventions for cardiovascular disease self‐management: a systematic review. European Journal of Preventive Cardiology 2016;23(8):801‐17.
Porter JB, Evangeli M, El‐Beshlawy A. Challenges of adherence and persistence with iron chelation therapy. International Journal of Hematology 2011;94(5):453‐60.
Porter J, Bowden DK, Economou M, Troncy J, Ganser A, Habr D, et al. Health‐related quality of life, treatment satisfaction, adherence and persistence in beta‐thalassemia and myelodysplastic syndrome patients with iron overload receiving deferasirox: results from the EPIC clinical trial. Anemia 2012;2012:297641.
Rachmilewitz EA, Giardina PJ. How I treat thalassemia. Blood 2011;118:3479‐88.
Reeves BC, Deeks JJ, Higgins JPT, Wells GA on behalf of the Cochrane Non‐Randomised Studies Methods Group. Chapter 13: Including non‐randomized studies. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Rund D, Rachmilewitz E. Beta‐thalassemia. New England Journal of Medicine. 2005;353(11):1135‐46.
Sabate E. Adherence to long‐term therapies: evidence for action. www.who.int/chp/knowledge/publications/adherence_report/en/ (accessed prior to 15 June 2017).
Schünemann HJ, Oxman AD, Higgins JPT, Vist GE, Glasziou P, Guyatt GH on behalf of the Cochrane Applicability and Recommendations Methods Group and the Cochrane Statistical Methods Group. Chapter 11: Presenting results and ‘Summary of findings’ tables. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Shah N, Jonassaint J, De Castro L. Patients welcome the Sickle Cell Disease Mobile Application to Record Symptoms via Technology (SMART). Hemoglobin 2014;38(2):99‐103.
Smith A. U.S. smartphone use in 2015. www.pewinternet.org/2015/04/01/us‐smartphone‐use‐in‐2015/ (accessed prior to 15 June 2017).
Smith C, Gold J, Ngo TD, Sumpter C, Free C. Mobile phone‐based interventions for improving contraception use. Cochrane Database of Systematic Reviews 2015, Issue 6. [DOI: 10.1002/14651858.CD011159.pub2]
Sterne JAC, Egger M, Moher D, editor(s) on behalf of the Cochrane Bias Methods Group. Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, et al. ROBINS‐I: a tool for assessing risk of bias in non‐randomised studies of interventions. BMJ 2016;355:i4919.
Taher A, Al Jefri A, Elalfy MS, Al Zir K, Daar S, Rofail D, et al. Improved treatment satisfaction and convenience with deferasirox in iron‐overloaded patients with beta‐thalassemia: results from the ESCALATOR trial. Acta Haematologica 2010;123(4):220‐5.
Thakkar J, Kurup R, Laba TL, Santo K, Thiagalingam A, Rodgers A, et al. Mobile telephone text messaging for medication adherence in chronic disease: a meta‐analysis. JAMA Internal Medicine 2016;176(3):340‐9.
Trachtenberg F, Vichinsky E, Haines D, Pakbaz Z, Mednick L, Sobota A, et al. Iron chelation adherence to deferoxamine and deferasirox in thalassemia. American Journal of Hematology 2011;86(5):433‐6.
Trachtenberg FL, Mednick L, Kwiatkowski JL, Neufeld EJ, Haines D, Pakbaz Z, et al. Beliefs about chelation among thalassemia patients. Health and Quality of Life Outcomes 2012;10:148.
Trachtenberg FL, Gerstenberger E, Xu Y, Mednick L, Sobota A, Ware H, et al. Relationship among chelator adherence, change in chelators, and quality of life in thalassemia. Quality of Life Research 2014;23(8):2277‐88.
Vekeman F, Sasane M, Cheng WY, Ramanakumar AV, Fortier J, Qiu Y, et al. Adherence to iron chelation therapy and associated healthcare resource utilization and costs in Medicaid patients with sickle cell disease and thalassemia. Journal of Medical Economics 2016;19(3):292‐303.
Walsh KE, Cutrona SL, Kavanagh PL, Crosby LE, Malone C, Lobner K, et al. Medication adherence among pediatric patients with sickle cell disease: a systematic review. Pediatrics 2014;134(6):1175‐83.
Ward R, Taha KM. Patient involvement as experts in the development and assessment of a smartphone app as a patient education tool for the management of thalassemia and iron overload syndromes. Hemoglobin 2016;40(5):323‐9.
Ware HM, Kwiatkowski JL. Evaluation and treatment of transfusional iron overload in children. Pediatric Clinics of North America 2013;60(6):1393‐406.
Weatherall DJ. The definition and epidemiology of non‐transfusion‐dependent thalassemia. Blood Reviews 2012;26 Suppl 1:S3‐6.
Whitehead L, Seaton P. The effectiveness of self‐management mobile phone and tablet apps in long‐term condition management: a systematic review. Journal of Medical Internet Research 2016;18(5):e97.
